Gofen & Glossberg’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Gofen & Glossberg’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$7K	Sell	25,000 -25,000	-50%	-$9.05K	﹤0.01%	582
2022 Q3	$21K	Buy	50,000 +25,000	+100%	+$9.94K	﹤0.01%	551
2022 Q2	$11K	Hold	25,000	–	–	﹤0.01%	561
2022 Q1	$32K	Hold	25,000	–	–	﹤0.01%	601
2021 Q4	$33K	Hold	25,000	–	–	﹤0.01%	609
2021 Q3	$52K	Hold	25,000	–	–	﹤0.01%	597
2021 Q2	$40K	Hold	25,000	–	–	﹤0.01%	564
2021 Q1	$56K	Hold	25,000	–	–	﹤0.01%	541
2020 Q4	$62K	Hold	25,000	–	–	﹤0.01%	522
2020 Q3	$62K	Hold	25,000	–	–	﹤0.01%	466
2020 Q2	$89K	Hold	25,000	–	–	﹤0.01%	434
2020 Q1	$59K	Hold	25,000	–	–	﹤0.01%	422
2019 Q4	$55K	Hold	25,000	–	–	﹤0.01%	469
2019 Q3	$46K	Hold	25,000	–	–	﹤0.01%	447
2019 Q2	$36K	Hold	25,000	–	–	﹤0.01%	440
2019 Q1	$49K	Hold	25,000	–	–	﹤0.01%	436
2018 Q4	$33K	Hold	25,000	–	–	﹤0.01%	425
2018 Q3	$62K	Hold	25,000	–	–	﹤0.01%	459
2018 Q2	$84K	Hold	25,000	–	–	﹤0.01%	441
2018 Q1	$106K	Hold	25,000	–	–	﹤0.01%	446
2017 Q4	$83K	Hold	25,000	–	–	﹤0.01%	478
2017 Q3	$96K	Hold	25,000	–	–	﹤0.01%	461
2017 Q2	$110K	Hold	25,000	–	–	﹤0.01%	455
2017 Q1	$91K	Hold	25,000	–	–	﹤0.01%	464
2016 Q4	$67K	Hold	25,000	–	–	﹤0.01%	444
2016 Q3	$82K	Hold	25,000	–	–	﹤0.01%	436
2016 Q2	$84K	Hold	25,000	–	–	﹤0.01%	436
2016 Q1	$61K	Hold	25,000	–	–	﹤0.01%	448
2015 Q4	$82K	Hold	25,000	–	–	﹤0.01%	435
2015 Q3	$86K	Hold	25,000	–	–	﹤0.01%	438
2015 Q2	$33K	Hold	25,000	–	–	﹤0.01%	451
2015 Q1	$21K	Hold	25,000	–	–	﹤0.01%	457
2014 Q4	$10K	Hold	25,000	–	–	﹤0.01%	457
2014 Q3	$109K	Hold	25,000	–	–	﹤0.01%	434
2014 Q2	$124K	Hold	25,000	–	–	0.01%	433
2014 Q1	$136K	Hold	25,000	–	–	0.01%	457
2013 Q4	$152K	Hold	25,000	–	–	0.01%	441
2013 Q3	$166K	Hold	25,000	–	–	0.01%	410
2013 Q2	$127K	Buy	+25,000	New	+$127K	0.01%	414

Other funds holding NYMX

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FCFC

First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return

Gofen & Glossberg's NYMX Position: Q4 2022 in Review

Gofen & Glossberg reduced its Nymox Pharmaceutical Corp (NYMX) stake by 50% in Q4 2022, selling an estimated $9.05K and leaving 25,000 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #582.

Gofen & Glossberg first reported a position in NYMX in Q2 2013 and has held it in 39 quarters since. The position peaked at $166K in Q3 2013. 37 funds tracked by Wall St. Rank hold NYMX as of Q4 2022.

Gofen & Glossberg held 25,000 shares of Nymox Pharmaceutical Corp worth $7K as of Q4 2022.
Gofen & Glossberg sold 25,000 Nymox Pharmaceutical Corp shares in Q4 2022, an estimated $9.05K.
Nymox Pharmaceutical Corp made up ﹤0.01% of Gofen & Glossberg's portfolio in Q4 2022, its #582 holding.
Gofen & Glossberg first reported a position in Nymox Pharmaceutical Corp in Q2 2013 and has held it in 39 quarters since.
Gofen & Glossberg's Nymox Pharmaceutical Corp position peaked at $166K in Q3 2013.
37 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2022.

Based on Gofen & Glossberg's 13F filing for Q4 2022, filed 13 Jan 2023.